National Institutes of Health Identifies Signaling Mechanism Behind GLP-1 Weight Loss Plateau
A National Institutes of Health study team discovered a neurochemical mechanism that explains plateaus in weight loss. The researchers’ results were reported in the journal Nature Metabolism. Cyclic adenosine monophosphate, a crucial intracellular signaling molecule, is the focus of their research. A possible pharmacological route to get around treatment stalls is provided by this study.
GLP-1 receptor agonists influence the brain’s circuits that control hunger. In order to lower calorie intake, these medications decrease stomach emptying and increase satiety. Even with ongoing treatment, the majority of patients eventually reach a plateau. Because of this, it is still unclear why different patients respond differently to drugs.
The scientists observed biochemical activity within brain neurons using fluorescence imaging. In order to track appetite regulation, they concentrated on the postrema region. This method made it possible to see intracellular signaling events up close. As a result, the method offered high-resolution understanding of pharmacodynamics at the neuron level.
The degree of signaling increase in targeted neurons is directly correlated with semaglutide effectiveness. Not every neuron in the population experienced this rise. While some neurons displayed brief increases, others sustained consistently high levels. Given this, inter-patient variability is probably caused by different reactions.
The scientists concluded that phosphodiesterase 4’s enzymatic breakdown was the cause of the decrease in particular neurons. To test this notion, they combined semaglutide with an authorized inhibitor. In previously ephemeral neurons, our intervention maintained increased signaling levels. As a result, the combination changed cellular signaling to support ongoing medication effectiveness.
The results show that phosphodiesterase 4 inhibition is a manageable target for preserving medication efficacy. Over several hours, the current study tracked changes in neurons. Accordingly, the team intends to follow up research exploring signaling patterns over longer timeframes. Combination treatment approaches for metabolic control may be influenced by these findings.
